Journal of Clinical Oncology, Vol 26, No 5 (February 10), 2008: pp. 729-735
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.3222
Clinical Application of the 70-Gene Profile: The MINDACT Trial
Fatima Cardoso,
Laura Van't Veer,
Emiel Rutgers,
Sherene Loi,
Stella Mook,
Martine J. Piccart-Gebhart
From the Jules Bordet Institute, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, the Netherlands; and Peter MacCallum Cancer Centre, Melbourne, Australia
Corresponding author: M.J. Piccart-Gebhart, PhD, MD, Medical Oncology, Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium; e-mail: martine.piccart{at}bordet.be
The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.
Supported by the European Commission Framework Programme VI, the Breast Cancer Research Foundation, the European Breast Cancer Conference (EBCC) Breast Cancer Working Group, the Fondation Belge Contre Le Cancer, the Susan G. Komen for the Cure Foundation, Jacqueline Seroussi Memorial Foundation for Cancer Research, the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group, the Center of Biomedical Genetics, the Dutch Health Care Insurance Board, and the Dutch National Genomic Initiative Cancer Genomics Program.
Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. C. Culhane, T. Schwarzl, R. Sultana, K. C. Picard, S. C. Picard, T. H. Lu, K. R. Franklin, S. J. French, G. Papenhausen, M. Correll, et al.
GeneSigDB--a curated database of gene expression signatures
Nucleic Acids Res.,
November 24, 2009;
(2009)
gkp1015v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A H Sims
Bioinformatics and breast cancer: what can high-throughput genomic approaches actually tell us?
J. Clin. Pathol.,
October 1, 2009;
62(10):
879 - 885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cianfrocca and W. Gradishar
New Molecular Classifications of Breast Cancer
CA Cancer J Clin,
September 1, 2009;
59(5):
303 - 313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Mandrekar and D. J. Sargent
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
J. Clin. Oncol.,
August 20, 2009;
27(24):
4027 - 4034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Correa Geyer and J. S. Reis-Filho
Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet?
International Journal of Surgical Pathology,
August 1, 2009;
17(4):
285 - 302.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Fowler, R. J. Santen, and D. C. Allred
"Dwarf" Estrogen Receptor in Breast Cancer and Resistance to Tamoxifen
J. Clin. Oncol.,
July 20, 2009;
27(21):
3413 - 3415.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
Ann. Onc.,
July 1, 2009;
20(7):
1157 - 1162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Hugh, J. Hanson, M. C. U. Cheang, T. O. Nielsen, C. M. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, et al.
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
J. Clin. Oncol.,
March 10, 2009;
27(8):
1168 - 1176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. S. Russell, I. H. Kunkler, G. van Tienhoven, P. A. Canney, J. Thomas, J. Bartlett, M. J. van de Vijver, Y. Belkacemi, J. R. Yarnold, and P. J. Barrett-Lee
Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?
J. Clin. Oncol.,
February 20, 2009;
27(6):
996 - 997.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sotiriou and L. Pusztai
Gene-Expression Signatures in Breast Cancer
N. Engl. J. Med.,
February 19, 2009;
360(8):
790 - 800.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Dowsett and A. K. Dunbier
Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Clin. Cancer Res.,
December 15, 2008;
14(24):
8019 - 8026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Hassett, M. E. Hughes, J. C. Niland, S. B. Edge, R. L. Theriault, Y.-N. Wong, J. Wilson, W. B. Carter, D. W. Blayney, and J. C. Weeks
Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer
J. Clin. Oncol.,
December 1, 2008;
26(34):
5553 - 5560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem.,
December 1, 2008;
54(12):
e11 - e79.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Duffy and J. Crown
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Clin. Chem.,
November 1, 2008;
54(11):
1770 - 1779.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J.T. Rutgers, L. Pusztai, and R. Bernards
Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening?
Ann Intern Med,
September 2, 2008;
149(5):
357 - 357.
[Full Text]
[PDF]
|
 |
|
|